Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HLX43 combined with HLX07 or serplulimab in advanced or metastatic colorectal cancer
CTR20255223Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in colorectal adenocarcinoma, sponsored by HyBioPharma. Started Feb 2026; status: active.
02
Drugs
HLX43
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20255223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255223.